Equities

Nanjing Vishee Medical Technology Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Nanjing Vishee Medical Technology Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)56.18
  • Today's Change-0.41 / -0.72%
  • Shares traded940.49k
  • 1 Year change+84.99%
  • Beta1.7169
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nanjing Vishee Medical Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of rehabilitation medical equipment and products. The Company’s products are mainly electrical stimulation, magnetic stimulation, electrophysiological equipment, consumables and accessories and other rehabilitation medical equipment and products, such as pelvic floor muscle recovery equipment, transcranial magnetic stimulator, neonatal electroencephalography measuring instrument, rectal electrode, micro current stimulator and others. The Company mainly conducts its businesses within the domestic market.

  • Revenue in CNY (TTM)433.83m
  • Net income in CNY125.95m
  • Incorporated2001
  • Employees639.00
  • Location
    Nanjing Vishee Medical Technology Co LtdBlock 9#19 Ningshuang Road, Yuhuatai DistrictNANJING 210012ChinaCHN
  • Phone+86 2 569670036
  • Fax+86 2 569670037
  • Websitehttps://www.vishee.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hangzhou Ags Medtech Co Ltd668.70m272.95m4.98bn744.0018.192.00--7.443.373.378.2530.670.26733.3111.94898,793.6010.91--11.39--69.67--40.82--18.27--0.001--25.14--35.06------
Zhejiang Orient Gene Biotech Co Ltd842.11m-479.50m5.01bn2.28k--0.787--5.94-2.48-2.484.3731.550.1071.443.39369,997.60-6.6821.19-7.7726.7434.8858.52-62.4332.423.86--0.046224.780.94617.65-33.06--138.80--
Assure Tech (Hangzhou) Co Ltd462.72m120.87m5.04bn741.0041.720.9768--10.900.95110.95113.6440.620.08092.222.17624,449.302.1123.692.3028.0130.3264.6126.1147.6511.28--0.001218.787.4220.8535.8528.6963.16--
Nanjing Vishee Medical Technology Co Ltd433.83m125.95m5.42bn639.0043.033.27--12.491.321.324.5317.310.24114.0014.42678,922.307.008.397.639.2061.2471.6229.0332.766.54--0.018259.13-13.454.64-25.160.447439.73--
Hangzhou Biotest Biotech Co Ltd478.69m102.57m5.44bn603.0052.282.33--11.360.69640.69643.0615.660.19133.205.70793,854.104.0223.634.2526.2050.5756.5921.0041.4713.08--0.0000834.4226.5321.7859.0143.1244.08--
SWS Hemodialysis Care Co Ltd733.59m113.43m5.52bn1.10k48.843.13--7.530.35380.35382.295.520.35772.806.23665,688.205.235.685.836.5445.7145.7914.6116.065.25--0.001428.46-17.8031.86-63.55--24.70--
Shanghai Aohua Phtlctrcty Endscp Co Ltd671.62m-72.38m5.76bn1.22k--4.62--8.57-0.5475-0.54755.109.250.38341.022.29552,775.60-4.143.01-5.153.3461.7968.86-10.807.521.57--0.208643.3010.5420.28-63.68-16.8623.29--
Qingdao NovelBeam Technology Co Ltd571.80m174.33m5.85bn841.0033.624.44--10.231.451.454.7610.990.38170.99325.67679,901.1011.3912.7012.6114.1164.3463.1529.8433.963.4351.040.105840.95-5.9011.86-7.1113.4813.44--
Jiangsu Bioperfectus Technologies Co Ltd339.03m-25.96m5.88bn592.00--1.98--17.36-0.3096-0.30964.0435.380.09031.856.13572,683.70-0.691920.36-0.79624.5558.2262.71-7.6631.893.22--0.132928.76-13.293.9099.46---9.88--
Shenzhen Lifotronic Technology Co Ltd1.05bn251.02m5.93bn1.67k23.412.82--5.620.59070.59072.474.900.38552.515.74631,202.608.9814.0312.1017.3461.0362.4623.3027.253.00--0.140639.010.202422.125.1227.99-1.6318.64
Data as of Feb 11 2026. Currency figures normalised to Nanjing Vishee Medical Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

3.24%Per cent of shares held by top holders
HolderShares% Held
Galaxy Asset Management Co., Ltd.as of 30 Jun 2025146.44k0.59%
Maxwealth Fund Management Co., Ltd.as of 30 Jun 2025103.76k0.42%
CCB Principal Asset Management Co., Ltd.as of 30 Jun 202594.29k0.38%
Beixin Ruifeng Fund Management Co., Ltd.as of 30 Jun 202590.00k0.36%
Hwabao WP Fund Management Co., Ltd.as of 30 Jun 202581.01k0.33%
China Southern Asset Management Co., Ltd.as of 30 Jun 202572.12k0.29%
China Fund Management Co., Ltd.as of 30 Jun 202569.63k0.28%
E Fund Management Co., Ltd.as of 30 Jun 202554.63k0.22%
Springs Capital (Beijing) Ltd.as of 30 Jun 202550.00k0.20%
Bank of Beijing Scotiabank Asset Management Co., Ltd.as of 30 Jun 202540.48k0.16%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.